GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Stopped Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE drug product, GTB-3650.

Conditions

• High-risk Myelodysplastic Syndromes
• Acute Myelogenous Leukemia
• Systemic Mastocytosis
• Mast Cell Leukemia

Interventions

• DRUG: GTB-3550 TriKE® Phase I
• DRUG: GTB-3550 TriKE® Phase II

Sponsor

GT Biopharma, Inc.